Actively Recruiting
Safety and Effects of Single Doses of HSK56630 in Healthy Adults Aged 18 to 60
Led by Haisco Pharmaceutical Group Co., Ltd. · Updated on 2026-06-24
40
Participants Needed
1
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, pharmacokinetics PK, and pharmacodynamics PD of HSK56630, an investigational drug, in healthy adult volunteers. This first-in-human, phase 1 study is randomized, double-blind, placebo-controlled, and uses a single ascending dose SAD design to gather initial human data on HSK56630. The study aims to assess how the drug behaves in the body and its preliminary effects. Participants receive a single oral dose of either HSK56630 tablets or placebo in a sequential manner with ascending dose levels. The study is conducted at a single center and involves random assignment to either the experimental drug or placebo groups. The treatment period consists of a single dose followed by monitoring for 8 days to evaluate safety, drug levels, and biological responses. During the 8-day study period, participants attend scheduled visits for physical exams, vital sign checks, laboratory tests including blood work, and other safety assessments. Researchers also measure how the drug is absorbed and processed by the body, along with its pharmacodynamic effects. Participants are closely observed throughout the study to monitor for any adverse effects and to collect data on drug behavior and tolerability.
CONDITIONS
Brief Title
First-in-human Study of HSK56630 in Healthy Subjects
Research Team
C
Chen Meixia
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here